Reduced-Dose Radiation Shows Durable Control
Single-arm cohort findings contrast with interim results from NRG-HN005, underscoring ongoing uncertainty around treatment deintensification.
-
By
-
Andrea Surnit
-
May 8, 2026
-
Clinical Scorecard: Reduced-Dose Radiation Shows Durable Control
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Deintensified 60-Gy radiotherapy regimen with concurrent cisplatin; intensity-modulated radiotherapy used. |
| Target Population | |
| Care Setting | |
Key Highlights
- 5-year locoregional recurrence rate of 3.4%.
- Progression-free survival at 5 years was 86.5%.
- Overall survival at 5 years was 92.4%.
- Nodal stage was the only independent factor for progression-free survival.
- No locoregional recurrences in lower-risk patients treated with radiotherapy alone.
- Distant recurrence occurred in 7.3% of patients at 5 years.
- Median time to progression was 1.9 years.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Prolonged surveillance may be warranted due to late recurrences.
Risks
Patient & Prescribing Data
Cisplatin at 30 mg/m² weekly was the preferred systemic therapy due to its efficacy in this patient population.
Clinical Best Practices
- Carefully select patients for deintensified treatment approaches.
- Ensure informed consent regarding treatment risks and benefits, including potential discrepancies in outcomes.
Related Resources & Content
